Actively Recruiting

Phase 2
Age: 30Years - 75Years
All Genders
NCT07537868

Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction

Led by October 6 University · Updated on 2026-05-08

80

Participants Needed

1

Research Sites

75 weeks

Total Duration

On this page

Sponsors

O

October 6 University

Lead Sponsor

M

Mansoura University

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a randomized controlled clinical trial designed to evaluate the therapeutic effects of Montelukast in patients diagnosed with Acute Myocardial Infarction (AMI). The study aims to investigate whether the administration of Montelukast influences inflammatory markers and the extent of cardiac injury following a heart attack.Participants will be randomly assigned to receive either the active medication or a placebo to provide high-quality evidence regarding the drug's potential cardioprotective and anti-inflammatory properties. The trial is conducted through the Faculty of Pharmacy and Faculty of Medicine at Mansoura University

CONDITIONS

Official Title

Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction

Who Can Participate

Age: 30Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 30 and 75 years
  • Diagnosed with STEMI within 6 hours of symptom onset
  • Undergoing PCI or thrombolysis treatment
  • Eligible for standard acute coronary syndrome therapy
  • Signed informed consent to participate
Not Eligible

You will not qualify if you...

  • Chronic use of anti-inflammatory drugs
  • Severe liver or kidney impairment
  • Allergy or hypersensitivity to Montelukast
  • Presence of autoimmune or inflammatory diseases
  • Cardiogenic shock, severe heart failure, or structural heart complications such as papillary muscle rupture
  • History of cardiopulmonary resuscitation
  • Severe and uncontrolled high blood pressure
  • Previous myocardial infarction
  • Active bleeding or visceral hemorrhage
  • Current malignant tumors, lymphomas, leukemias, or other serious diseases
  • Gastrointestinal surgery in the past 4 weeks affecting drug absorption
  • Family history of psychiatric disorders
  • Pregnancy or breastfeeding
  • Participation in another clinical trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mansoura Faculty of Medicine hospital

Al Mansurah, Egypt

Actively Recruiting

Loading map...

Research Team

A

Abdallah Alshammari, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction | DecenTrialz